<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28590">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02123316</url>
  </required_header>
  <id_info>
    <org_study_id>ECRL12008-003680-39</org_study_id>
    <secondary_id>2008-003680-39</secondary_id>
    <nct_id>NCT02123316</nct_id>
  </id_info>
  <brief_title>Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic Rhinitis</brief_title>
  <acronym>ECRL1</acronym>
  <official_title>Assessment of the Effectiveness of a Dermatophagoides Pteronyssinus Extract, Rated in Units of Mass and Administered Subcutaneously for the Treatment of Local Allergic Rhinitis. Randomized, Double-blind, Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miguel Blanca Gomez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Plaza del Hospital Civil</source>
  <oversight_info>
    <authority>Spain: Agencia Espa√±ola de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of an extract of Dermatophagoides pteronyssinus versus placebo in
      the treatment of local allergic rhinitis. The primary efficacy endpoint is the reduction in
      symptom scores and medication use in the active group compared to placebo.

      The influence of treatment in &quot;in vitro&quot; and &quot;in vivo&quot; objective parameters was also
      assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline Symptoms-Medication score at 1,3,6,12,18, and 24 months</measure>
    <time_frame>Baseline, month 1,3,6,12,18, and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients were provided a diary to score the severity of their symptoms and the use of rescue medication during 4 consecutive weeks.
Nasal symptoms of rhinorrhea, nasal congestion, sneezing, nasal itching, and ocular symptoms were recorded using a 4-point categorical scale from 0 to 3 (0: no symptoms, 1:mild, 2:moderate; 3:severe).
The use of rescue medication was recorded in the patient diary according to the following score:
Oral antihistamines (1 tablet = 1 point); intranasal corticosteroids (400mcg/day of beclometasone or equivalent = 1.4 points); and ocular antihistamines (1 dose = 1 point).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline response skin prick-test at 1,3,6,12,18, and 24 months</measure>
    <time_frame>Baseline, month 1,3,6,12,18, and 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline response to intradermal test at 1,3,6,12 and 24 months</measure>
    <time_frame>Baseline, month 1,3,6,12,18, and 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline flow cytometry study at 1,3,6,12,18, and 24 months</measure>
    <time_frame>Baseline, month 1,3,6,12,18, and 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline determination of tryptase, eosinophilic cationic protein, IgG, IgG4 and specific D. pteronyssinus-IgE by Immunoassay at 1,3,6,12,18, and 24 months</measure>
    <time_frame>Baseline, month 1,3,6,12,18 and 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline response to nasal allergen provocation test with Dermatophagoides pteronyssinus at 1,3,6,12,18 and 24 months</measure>
    <time_frame>Baseline, month 1,3,6,12,18 and 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Local Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Pangramin Plus D. pteronyssinus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pangramin Plus D. pteronyssinus 100% for subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pangramin Plus D. pteronyssinus</intervention_name>
    <description>Subcutaneous immunotherapy with Dermatophagoides pteronyssinus</description>
    <arm_group_label>Pangramin Plus D. pteronyssinus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior to study specific examinations the patient  has to give his/her written
             informed consent.

          -  Local allergic rhinitis induced by Dermatophagoides pteronyssinus (DP).

          -  Age: 18-55.

          -  Negative skin prick-test to DP

          -  Positive nasal allergen provocation test to DP (NAPT-DP) and/or nasal specific IgE
             (sIgE) to DP&gt;0.35 kU/L

          -  If applicable negative urine pregnancy test and willingness to use effective form of
             contraception for the duration of involvement in the study.

        Exclusion Criteria:

          -  Severe immunopathological or immunodeficiencies diseases.

          -  Treatment with beta-blockers, even when administered topically

          -  Severe psychological disorders

          -  Severe Atopic Dermatitis

          -  FEV1 &lt;70% predicted after appropriate pharmacological treatment

          -  History of hypersensitivity or intolerance to excipients and / or trial medication or
             other medication to be used for protocol

          -  Inability to adequately perform diagnostic tests or treatment

          -  Awareness of other inhaled allergens (perennial or seasonal) clinically relevant to
             the subject and that may interfere with the response evaluation

          -  Treatment with immunotherapy in the 5 years prior to his inclusion in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Blanca, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergy Unit, Regional University Hospital of Malaga, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>April 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Plaza del Hospital Civil</investigator_affiliation>
    <investigator_full_name>Miguel Blanca Gomez</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>local allergic rhinitis</keyword>
  <keyword>subcutaneous immunotherapy</keyword>
  <keyword>house dust mite allergy</keyword>
  <keyword>Dermatophagoides pteronyssinus allergy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
